Heart Researchers Find Neutral Results in Anti-Inflammatory ZEUS Trial
Study Details and Explanations
Paul Ridker and colleagues led this global Phase 3 study. The data were presented at the American Heart Association Scientific Meeting. They were also published in the New England Journal of Medicine. Researchers offer several explanations for the results. These include differences between ZEUS participants and those in prior trials. They also note the distinction between targeting IL-6 and other inflammatory pathways.
ZEUS Trial and Ziltivekimab
Inflammation directly increases cardiovascular disease risk. The ZEUS study tested a drug targeting interleukin-6 (IL-6). IL-6 is a secondary inflammatory molecule. IL-6 inhibitors are used for autoimmune disorders. Ziltivekimab reduced IL-6 levels. Yet, it did not lower cardiovascular event incidence versus placebo.
Clinical Research Importance
Ridker stressed the vital role of clinical research. Science does not offer immediate definitive answers. It relies on a process of trial and error. Past studies confirmed anti-inflammatory potential in reducing heart attacks and strokes. The core challenge is finding the optimal drug for each patient type.
Comparison with CANTOS
The CANTOS study, also led by Ridker, provides context. CANTOS investigated IL-1b, an intermediate interleukin. It showed a significant decrease in recurrent heart attacks and strokes. In contrast, ZEUS tested ziltivekimab. This monoclonal antibody targets a similar but different pathway at the IL-6 level.
Future Research Directions
Given the neutral outcomes, Ridker suggests focusing on superiortargets in the biological cascade. He mentions developing agents that inhibit NLRP3 inflammasome, an upstream target. Alternatively, distal IL-6 inhibition could work. However, the ZEUS patient group might not have been suitable.
ZEUS Population Analysis
ZEUS participants were older by an average of ten years than in CANTOS. They also had pronounced renal disease, diabetes, and chronic heart failure. Ridker noted limited therapeutic benefit in patients with irreversible conditions. Future IL-6 inhibition studies focus on earlier, modifiable disease stages.
Primary Outcomes and Safety
The primary outcome—combined heart attack, stroke, or cardiovascular death—showed no statistically significant difference. The rate was 561 in the treatment group versus 565 in placebo. Safety data were encouraging. There was no negative impact on overall mortality, though minor infection increases occurred.
Guidance and Existing Therapies
Authors urge more studies to clarify the optimal patient group for anti-inflammatory therapy. However, LoDoCo2 and COLCOT studies already proved colchicine's efficacy in stable atherosclerotic disease. The FDA approved low-dose colchicine for this purpose.
Clarifying ZEUS Findings
Ridker clarified that ZEUS did not prove efficacy for this drug in this specific context. It is vital to remember proven anti-inflammatories like low-dose colchicine. Integrating ZEUS with prior studies guides future research.
Preventive Care and Other Drugs
Ridker highlighted improving basic preventive care. Proper diet, exercise, and smoking cessation reduce inflammation and cardiac risk. Common drugs like statins and GLP-1 receptor agonists, such as semaglutide and tirzepatide, also have relevant anti-inflammatory properties.
Medical Principle and Screening
Ridker emphasized a core medical principle: „Doctors do not treat what they do not measure.”The American College of Cardiology recently requested extensive screening for high-sensitivity C-reactive protein (hsCRP). This accessible blood test indicates significant inflammatory risk.